الإمارات العربية المتحدة - الإنجليزية - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store france - 10 glass vials - infusion - 4 g/500 mg - infections-antibacterial

الإمارات العربية المتحدة - الإنجليزية - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store germany - 10 glass ampoules x 3 ml - injection - 25 mg/ml - musculoskeletal ,joint diseases-rheumatic diseases , gout

الإمارات العربية المتحدة - الإنجليزية - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store france - 25 glass vials - injection - 1 g/vial - infections-antibacterial

المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

panpharma, france - bupivacaine - solution for injection - 5 mg/ml,

الفلبين - الإنجليزية - FDA (Food And Drug Administration)

panpharma-meinz pharmaceutical corp - ceftriaxone sodium - sodium for injection iv / im - 1g

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 8 mg/2ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

multichem nz limited - droperidol 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: droperidol 0.5 mg/ml excipient: mannitol nitrogen sodium hydroxide tartaric acid water for injection - droperidol is indicated for the prevention and treatment of post-operative nausea and vomiting in adults and children (> 2 years of age).